RSV Vaccine Could Protect High-Risk Adults Under 60, Pfizer Says

ToplineA late-stage trial of Pfizer’s RSV vaccine showed promising results in adults under 60 years old, suggesting the shot could help people as young as 18, the company announced Tuesday, amid an effort to expand the vaccine’s availability to more people who are at a higher risk to the potentially lethal infection.Pfizer said the shot—approved for adults age 60 and older—had similar effects in adults over age 18. ... [+] Getty Images Key FactsPfizer’s vaccine, marketed as Abrysvo, resulted in an immune re ...